A Bioinformatic Investigation into the Role of ITGB1 in Cancer Prognosis and Therapeutic Resistance

Abstract

Integrin {beta} 1 is a crucial transmembrane protein that regulates cellular adhesion, migration, and signal transduction, processes essential for cancer progression. This study investigates the role of ITGB1, the gene that encodes Integrin {beta}1, in various cancers using bioinformatics tools. By analyzing gene expression data across different cancer types and normal tissues, the study identifies significant upregulation of ITGB1 in 12 cancer types. We find elevated expression of ITGB1 is associated with poor prognosis in multiple tumors, suggesting its potential as a biomarker for cancer progression and therapeutic resistance. Further analysis reveals ITGB1s correlation with chemoresistance and immunoresistance genes, highlighting its involvement in cancer treatment evasion. The study also explores the expression and role of genes that are highly related to ITGB1 in tumor and patient prognosis, offering insights into potential molecular pathways and therapeutic targets. These findings underscore the clinical relevance of ITGB1 in cancer prognosis and therapy.